Fistula Graft with Capping Member and Plug for Sealing

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current methods for treating fistulae often result in complications such as incontinence and impaired sphincter control, and existing treatments for gastrointestinal fistulae are inadequate, with limited effectiveness in sealing off fistula openings and promoting healing.

Innovation Solution

A medical graft product comprising a biocompatible graft body with a capping member and an elongate plug member, configured to block the primary fistula opening and extend into the fistula tract, using remodelable materials like submucosa to promote tissue ingrowth and healing, and incorporating anchoring adaptations for secure placement.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If surgical fistulotomy is performed to treat fistulae, then the fistula tract is cleared and healing is promoted, but sphincter muscle is divided causing incontinence and impaired sphincter control

Engineering Contradiction:
Improvehealing effectivenessVSAvoidincontinence and sphincter control impairment
Core Design Contradiction:
ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The fistula treatment is divided into two distinct stages: first placing a seton to isolate and drain the fistula tract, then later injecting sealant or sclerosant to close the tract. This segmentation allows the sphincter to be preserved during the first stage while achieving closure in the second stage, avoiding the incontinence problem caused by immediate surgical division.

Inventive Principle:
Principle #1Segmentation

Solution Approach 2:

The seton is placed in advance to establish drainage and isolate the fistula tract from surrounding tissues before the definitive closure procedure. This preliminary action prepares the tract for subsequent sealant injection while maintaining sphincter integrity, preventing the harmful effect of premature sphincter division.

Inventive Principle:
Principle #10Preliminary action

2Reliability

If sealant or sclerosant is injected into an unprepared infected fistula, then fistula closure is achieved, but infection flares up and abscess formation increases

Engineering Contradiction:
Improvefistula closure effectivenessVSAvoidinfection flare-up and abscess formation
Core Design Contradiction:
ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The seton is placed in advance to drain the infected fistula tract and allow inflammation to subside before sealant injection. This preliminary drainage action reduces the bacterial load and prepares the tract for safe closure, preventing infection flare-up when the sealant is later injected.

Inventive Principle:
Principle #10Preliminary action

Solution Approach 2:

The seton acts as a protective measure by establishing continuous drainage and isolating the infected tract from surrounding healthy tissues before the closure procedure. This beforehand cushioning prevents the harmful effect of infection flare-up that would occur if sealant were injected directly into an active infection.

Inventive Principle:
Principle #11Beforehand cushioning (Prior cushioning)

3Ease of operation

If spontaneous closure of fistulae is awaited, then non-surgical treatment is provided, but closure occurs in less than 30% of cases requiring prolonged preparation time

Engineering Contradiction:
Improvenon-surgical treatment approachVSAvoidclosure rate
Core Design Contradiction:
Ease of operationVSReliability

Solution Approach 1:

The seton serves as an intermediary device that facilitates the closure process by draining the fistula tract and preparing it for eventual closure. This intermediary action increases the closure rate from less than 30% to a much higher success rate, while still maintaining a relatively non-surgical approach compared to immediate fistulotomy.

Inventive Principle:
Principle #24Intermediary (Mediator)

Data Source

PatentUS10470749B2Fistula grafts and related methods and systems useful for treating gastrointestinal and other fistulae
Publication Date: 2019.11.12 COOK BIOTECH INC
  • US10470749B2 patent drawing
  • US10470749B2 patent drawing
  • US10470749B2 patent drawing

AI summary

Described are medical graft products, systems, and methods useful for treating fistulae, particularly enterocutaneous fistulae. Certain products of the invention are configured to have portions residing in and around a primary fistula opening in a wall of the alimentary canal. One such product includes a biocompatible graft body which is configured to block at least the primary opening. The graft body includes a capping member connected to an elongate plug member. The capping member is configured to contact portions of the alimentary canal wall adjacent to the primary opening, and the elongate plug member is configured to extend into at least a portion of the fistula. A graft product of this sort may be particularly adapted to allow a portion of the capping member to be positioned alongside an exterior, lateral surface of the plug member, e.g., when placed in a delivery device lumen. Such a capping member may be hingedly or non-hingedly coupled to the elongate plug member.